HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HTG Molecular Diagnostics (NASDAQ: HTGM ) stock is falling on Tuesday after the company announced a Chapter 11 bankruptcy filing. According to this filing, HTG Molecular Diagnostics will operate as a “debtor-in-possession” business during the bankruptcy.

Why Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?

TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA.

HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention

TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business.

HTG Highlights the Advantages of Its Drug Discovery Engine

TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights.

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights

TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the American Association for Cancer Research Annual Meeting (AACR) April 16-19 in Orlando, Florida.

HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19

TUCSON, Ariz., Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of its drug discovery business unit, including the filing of a patent application directed towards its first therapeutics target, and announced that its management team will be hosting in-person meetings at the LifeSci Partners 2023 Corporate Access Event from January 9-11, 2023 in San Francisco, CA.

HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

Preliminary full year 2022 unaudited revenue of $6.4 million

HTG Announces Certain Preliminary 2022 Unaudited Financial Results

TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis,” hosted on Tuesday, December 13, 2022.

HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series

TUCSON, Ariz., Dec. 23, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the closing of its previously announced public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire five years from the date of issuance, and the Series A-2 warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire twenty-four months from the date of issuance.

HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering

TUCSON, Ariz., Dec. 21, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the pricing of a public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants will have an exercise price of $7.50 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-2 warrants will have an exercise price of $7.50 per share, will be exercisable immediately upon issuance and will expire twenty-four months from the date of issuance. The closing of the offering is expected to occur on or about December 23, 2022, subject to the satisfaction of customary closing conditions.

HTG Molecular Diagnostics Announces Pricing of a $10 Million Public Offering

Some investors of HTG Molecular Diagnostics (NASDAQ: HTGM ) got a big surprise today. Due to a reverse share split, HTGM stock is suddenly more expensive.

What Is Going on With HTG Molecular Diagnostics (HTGM) Stock Today?

TUCSON, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced that as a result of its one-for-twelve reserve stock split which became effective at 4:15 p.m. Eastern Time on December 20, 2022, its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) effective with the open of the market tomorrow, Wednesday, December 21, 2022. HTG's common stock will continue to trade under the ticker symbol “HTGM.”

HTG Announces One-for-Twelve Reverse Stock Split

Amyris

Landos Biopharma

Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Biotech Penny Stocks Under $3 To Watch Right Now

Akebia Therapeutics

Bone Biologics Corp

Hillstream Biopharma

Kalera PLC

Pagaya Technologies Ltd

SINTX Technologies Inc

Sio Gene Therapies

Venator Materials

Wearable Devices Ltd

Penny stocks to watch trading under $1 right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch

Faraday Future Intelligent Electric

Tonix Pharmaceuticals Hld

Need help researching penny stocks to buy? Use these tips The post How to Conduct Due Diligence on Penny Stocks, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Conduct Due Diligence on Penny Stocks, 3 Tips

Abeona Therapeutics

Harpoon Therapeutics Inc

This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023

Three Small-Cap Biotech Stocks to Consider Now

HTG Molecular Diagnostics (NASDAQ: HTGM ) stock is rocketing higher on Monday as investors prepare for a major event on Dec. 13. That's when the company will hold its HTG Therapeutics key opinion leader webinar.

Dear HTGM Stock Fans, Mark Your Calendars for Dec. 13

Low float penny stocks under $1 to watch after AMAM stock explodes over 500%. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 Low Float Stocks Under $1 To Watch

TUCSON, Ariz., Dec. 09, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis”, on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time.

HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series

TUCSON, Ariz., Dec. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced there will be at least eight scientific abstracts featuring HTG's proprietary HTG EdgeSeq™ technology presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS 2022) and at the 64th Annual American Society of Hematology (ASH) Annual Meeting.

HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 21.15% and 44.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates

TUCSON, Ariz., Nov. 10, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today reported financial results for the quarter ended September 30, 2022 and provided recent business highlights.

HTG Molecular Diagnostics Reports Third Quarter 2022 Results

TUCSON, Ariz. and PARIS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, and OmiCure®, a leading European digital health company that develops and markets explainable AI-based therapeutic decision support software, announced a collaboration with OmiCure to implement the HTG Transcriptome Panel (HTP) as an alternative to RNA-Seq to inform the OmiCure test and help guide therapeutic decision-making across several cancer types.

HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

TUCSON, Ariz., Oct. 12, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, completed its planned milestones for the third quarter of 2022, further advancing its transcriptome-informed approach to drug design and discovery utilizing the company's proprietary HTG EdgeSeq technology.

HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery

TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) --  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

News for HTG Molecular Diagnostics Stock (HTGM)